Fig. 1

ST2825 prevents S-phase progression in human dermal fibroblasts (hDF) and OA SFs. Effect of ST2825 on hDF (A, B, C) and OA-SFs (D, E). A DAPI-based cell viability assay identified the total number of cells among different conditions in hDF treated with 0, 5, 10, and 30 μM of ST2825 for 24 h. B Changes in cell number of hDF at 24, 48, and 72 h after the incubation with 5 and 10 μM of ST2825. C Quantification of the percentage of cells in various phases of the cell cycle upon ST2825 treatment at 24, 48, and 72 h by imaging cytometry. D Increase in cell number of OA SF at 24, 48, and 72 h after the incubation with 5 and 10 μM of ST2825. E Increase in cell number of OA SF at 24, 48, and 72 h after the incubation with 5 and 10 μM of ST2825. N = 3; two-way ANOVA and Dunnett’s multiple comparisons test were used to determine statistical significance. *p < 0.05, **p < 0.01